| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA841: Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated) |
|
Medicine details |
|
| Medicine name | carfilzomib (Kyprolis®) |
| Formulation | 10 mg powder for solution for infusion, 30 mg powder for solution for infusion, 60 mg powder for solution for infusion |
| Reference number | 3987 |
| Indication | In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/01/2021 |
| NICE guidance | TA841: Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated) |